WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
These hilarious notices will make you do a double take
Richmond Mayor Stoney drops Virginia governor bid, he will run for lieutenant governor instead
Tiger Woods FINALLY reveals the three stars joining his TGL team next year
China vows to actively promote restoration of int'l flights
Pregnant Draya Michele, 39, and NBA star boyfriend Jalen Green, 22, host cherry
Maya Rudolph chimes in on the 'nepo baby' conversation revealing her famous parents
Arrest Lord Mountbatten's self
Review of UNWRA finds Israel did not express concern about staff
Germany's foreign minister visits Kyiv as Ukraine battles to hold off a Russian offensive
He's a former Disney Channel actor who starred in famous films before serving four years in prison